JP2019510830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510830A5 JP2019510830A5 JP2019503595A JP2019503595A JP2019510830A5 JP 2019510830 A5 JP2019510830 A5 JP 2019510830A5 JP 2019503595 A JP2019503595 A JP 2019503595A JP 2019503595 A JP2019503595 A JP 2019503595A JP 2019510830 A5 JP2019510830 A5 JP 2019510830A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- composition according
- formulation
- compound
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 9
- 239000000829 suppository Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 Bc(c(C=*)c1)c(*)cc1O Chemical compound Bc(c(C=*)c1)c(*)cc1O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318946P | 2016-04-06 | 2016-04-06 | |
| US62/318,946 | 2016-04-06 | ||
| PCT/AU2016/050674 WO2017173474A1 (en) | 2016-04-06 | 2016-07-28 | Improvements in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510830A JP2019510830A (ja) | 2019-04-18 |
| JP2019510830A5 true JP2019510830A5 (enExample) | 2019-09-05 |
Family
ID=60000141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503595A Pending JP2019510830A (ja) | 2016-04-06 | 2016-07-28 | がん処置における改善 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190160004A1 (enExample) |
| EP (2) | EP3939583A1 (enExample) |
| JP (1) | JP2019510830A (enExample) |
| KR (1) | KR20190016017A (enExample) |
| CN (1) | CN109475522A (enExample) |
| AU (2) | AU2016401508B2 (enExample) |
| CA (1) | CA3058479A1 (enExample) |
| IL (1) | IL262143A (enExample) |
| RU (1) | RU2018137897A (enExample) |
| SG (1) | SG11201808777UA (enExample) |
| WO (1) | WO2017173474A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3439642A4 (en) * | 2016-04-06 | 2019-11-13 | Noxopharm Limited | IMPROVEMENTS IN RADIOTHERAPY |
| EP3439644B1 (en) | 2016-04-06 | 2022-01-12 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| AU2021247415A1 (en) | 2020-03-30 | 2022-09-29 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
| WO2022204757A1 (en) * | 2021-03-30 | 2022-10-06 | Noxopharm Limited | Improved isoflavone formulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| EP1545206B1 (en) * | 2002-07-24 | 2020-03-04 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| JP2007525485A (ja) | 2003-11-19 | 2007-09-06 | ノボゲン リサーチ ピーティーワイ リミテッド | 複合的な放射線治療及び化学治療の組成物及び方法 |
| DE102005009515A1 (de) * | 2005-02-25 | 2006-09-07 | Exner, Heinrich, Dr. | Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren |
| WO2007035515A2 (en) * | 2005-09-15 | 2007-03-29 | Umd, Inc. | A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration |
| WO2009003229A1 (en) * | 2007-06-29 | 2009-01-08 | Novogen Research Pty Ltd | 2-substituted isoflavonoid compounds, medicaments and uses |
| WO2010022467A1 (en) * | 2008-08-29 | 2010-03-04 | Novogen Research Pty Ltd | Immunomodulating activities |
| KR20110004525A (ko) * | 2009-07-08 | 2011-01-14 | 동의대학교 산학협력단 | 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물 |
-
2016
- 2016-07-28 EP EP21176052.5A patent/EP3939583A1/en not_active Withdrawn
- 2016-07-28 CN CN201680086470.1A patent/CN109475522A/zh active Pending
- 2016-07-28 WO PCT/AU2016/050674 patent/WO2017173474A1/en not_active Ceased
- 2016-07-28 SG SG11201808777UA patent/SG11201808777UA/en unknown
- 2016-07-28 EP EP16897482.2A patent/EP3439651A4/en not_active Withdrawn
- 2016-07-28 AU AU2016401508A patent/AU2016401508B2/en not_active Ceased
- 2016-07-28 RU RU2018137897A patent/RU2018137897A/ru not_active Application Discontinuation
- 2016-07-28 CA CA3058479A patent/CA3058479A1/en not_active Abandoned
- 2016-07-28 JP JP2019503595A patent/JP2019510830A/ja active Pending
- 2016-07-28 KR KR1020187032107A patent/KR20190016017A/ko not_active Withdrawn
- 2016-07-28 US US16/091,688 patent/US20190160004A1/en not_active Abandoned
-
2018
- 2018-10-04 IL IL262143A patent/IL262143A/en unknown
-
2020
- 2020-06-23 AU AU2020204172A patent/AU2020204172A1/en not_active Abandoned
-
2021
- 2021-05-24 US US17/328,041 patent/US20210338576A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510830A5 (enExample) | ||
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2016536286A5 (enExample) | ||
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| JP2017518334A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| JP2017533925A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| JP2017524735A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2018537535A5 (enExample) | ||
| JP2015520770A5 (enExample) | ||
| CA2936551A1 (en) | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
| JP2019516739A5 (enExample) | ||
| JP2017503798A5 (enExample) | ||
| RU2018113718A (ru) | Новые соединения |